| Literature DB >> 22566916 |
Fabienne Tacchini-Cottier1, Tiffany Weinkopff, Pascal Launois.
Abstract
The murine model of Leishmania major infection has been an invaluable tool in understanding T helper differentiation in vivo. The initial evidence for a role of distinct CD4(+) T helper subsets in the outcome of infection was first obtained with this experimental model. The development of CD4(+) Th1 cells was associated with resolution of the lesion, control of parasite replication, and resistance to re-infection in most of the mouse strains investigated (i.e., C57BL/6). In contrast, differentiation of CD4(+) Th2 cells correlated with the development of unhealing lesions, and failure to control parasite load in a few strains (i.e., BALB/c). Since these first reports, an incredible amount of effort has been devoted to understanding the various parameters involved in the differentiation of these, and more recently discovered T helper subsets such as Th17 and T regulatory cells. The discovery of cross-talk between T helper subsets, as well as their plasticity force us to reevaluate the events driving a protective/deleterious T helper immune response following infection with L. major in mice. In this review, we describe the individual contributions of each of these CD4(+) T helper subsets following L. major inoculation, emphasizing recent advances in the field, such as the impact of different substrains of L. major on the pathogenesis of disease.Entities:
Keywords: IL-17; L. major; Leishmania; T helper cells; Th1; Th17; Th2; Treg
Year: 2012 PMID: 22566916 PMCID: PMC3342012 DOI: 10.3389/fimmu.2012.00032
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Origins of the .
| WHO code name | Origin of isolate | Country | |
|---|---|---|---|
| LV39 | MRHO/SU/59/P | Gerbil | Russia |
| Friedlin | MHOM/IL/80/Friedlin | Human | Israel |
| IR173 | MHOM/IR/-173 | Human | Iran |
| FEBNI | MHOM/IL/81/FEBNI | Human | Israel |
| Sd | MHOM/SN/74/Seidman | Human | Senegal |
.
Differential immune responses to .
| Control of infection | IL-4 | IL-10 | IL-17 | References | |
|---|---|---|---|---|---|
| LV39 | C57BL/6 (R)a | Over-expression of IL-4 (S) | n.d. | IL-17−/− (NA) | Leal et al. ( |
| BALB/c (S)b | IL-4−/− and IL-4Rα−/− (S); CD4+ specific IL-4Rα−/− (R) | IL-10−/− or IL-10R blockade (R) | IL-17−/− (NA) | Tacchini-Cottier and Launois (unpublished data) | |
| Friedlin | C57BL/6 (R) | Transient IL-4 in low dose inf but lesion resolution | IL-10−/− or IL-10R blockade (R); prevent parasite elimination from skin | IL-17−/− or rIL-17 (NA) | Belkaid et al. ( |
| BALB/c (S) | IL-4Rα−/− (S) | IL-10−/− (R) | IL-17−/− partially control parasitemia but no lesion resolution | ||
| IR173 | C57BL/6 (R) | rIL-4 injection (NA) | n.d. | n.d. | Sadick et al. ( |
| BALB/c (S) | IL-4−/− partially control inf but IL-4Rα−/− fully (R) | IL-10−/− or IL-10R blockade partially (R) | n.d. | ||
| FEBNI | C57BL/6 (R) | n.d. | n.d. | n.d. | Kopf et al. ( |
| BALB/c (S) | IL-4−/− and IL-4Rα−/− partial control of inf but (S); CD4+ specific IL-4Rα−/− (R) | n.d. | n.d. | ||
| Sd | C57BL/6 (S) | IL-4−/− and IL-4R blocked (S); undetectable IL-4 in WT | IL-10R blockade (R); IL-10 production by T cells controls Th1 response and pathology; IL-10 associated with unhealing lesions | Weak IL-17 production modulated by IL-27 | Kropf et al. ( |
| BALB/c (S) | IL-4−/− (NA) | IL-10R blockade partially (R) | n.d. |
.
NA: disease phenotype not altered; n.d., not determined.